glp-1 gip lilly LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes Glucose-dependent insulinotropic polypeptide receptor signaling
Description
As per claims, this will be especially effective in reducing cravings triggered by external cues or stress
When I first started seeing the headlines about GLP-1 medications for weight loss, I was skeptical
See visible results in weeks, not months
Pathogens 10 , 152 (2021)
Frequently Asked Questions How long does a tirzepatide weight loss plateau typically last
Long-term studies have shown that semaglutide GLP-1 remains effective and safe for weight loss over one to two years
